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Objective: Mifepristone is the only available glucocorticoid receptor antagonist. Only few adult patients
with hypercortisolism were treated to date by this drug. Our objective was to determine effectiveness
and tolerability of mifepristone in Cushing’s syndrome (CS).
Design: Retrospective study of patients treated in seven European centers.
Methods: Twenty patients with malignant (nZ15, 12 with adrenocortical carcinoma, three with
ectopic ACTH secretion) or benign (nZ5, four with Cushing’s disease, one with bilateral adrenal
hyperplasia) CS were treated with mifepristone. Mifepristone was initiated with a median starting dose
of 400 mg/day (200–1000). Median treatment duration was 2 months (0.25–21) for malignant CS,
and 6 months (0.5–24) for benign CS. Clinical (signs of hypercortisolism, blood pressure, signs of
adrenal insufficiency), and biochemical parameters (serum potassium and glucose) were evaluated.
Results: Treatment was stopped in one patient after 1 week due to severe uncontrolled hypokalemia.
Improvement of clinical signs was observed in 11/15 patients with malignant CS (73%), and 4/5
patients with benign CS (80%). Psychiatric symptoms improved in 4/5 patients within the first week.
Blood glucose levels improved in 4/7 patients. Signs of adrenal insufficiency were observed in 3/20
patients. Moderate to severe hypokalemia was observed in 11/20 patients and increased blood pressure
levels in 3/20 patients.
Conclusion: Mifepristone is a rapidly effective treatment of hypercortisolism, but requires close
monitoring of potentially severe hypokalemia, hypertension, and clinical signs of adrenal insufficiency.
Mifepristone provides a valuable treatment option in patients with severe CS when surgery is
unsuccessful or impossible.
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Cushing’s syndrome (CS) is a rare but serious disease
with significant morbidity and mortality due to
cardiovascular, metabolic, and infectious complications
(1, 2). Transsphenoidal surgery is the treatment of
choice for Cushing’s disease (CD) and is usually followed
by pituitary irradiation or by bilateral adrenalectomy if
surgery has failed (3). In malignant CS, surgery remains
the first-line treatment in adrenocortical carcinoma
(ACC) and ectopic ACTH secretion (EAS) while
chemotherapy and/or radiotherapy are reserved for
advanced disease (4, 5). Medical management of
hypercortisolism can thus be used in four circum-
stances: during the period required for localization of
the ACTH source, in preparation for surgery, followingndocrinologyradiation therapy to bridge its delayed efficacy or in
metastatic disease as part of a multimodal approach.
Several drugs have been advocated, each having
advantages and drawbacks. For example, o,p 0-dichloro-
diphenildichloroethane is effective in controlling cortisol
excess in about 50–80% of cases, and also has
antitumoral effects due to its adrenolytic activity (6).
However, maximum efficacy is delayed and the drug is
frequently poorly tolerated due to a narrow therapeutic
window (7, 8). Other drugs like ketoconazole or
metyrapone may act more rapidly but are often only
partially effective and associated with significant
adverse events (e.g., serious hepatotoxicity, hyperten-
sion or hypokalemia) (9, 10). In cases of drug
intolerance or unresponsitivity, an alternative medical
treatment should be useful.DOI: 10.1530/EJE-09-0098
Online version via www.eje-online.org
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coid receptor antagonist (11, 12). It was discovered in
the early 1980’s (13), but due to its strong antiprogestin
activity it has mainly been used as a contragestive pill.
Owing to the controversy related to this use of
mifepristone, there is presently limited experience
concerning the use of mifepristone in hypercortisolism.
To date only 21 patients (including two children) were
reported to have been treated with mifepristone, mostly
for short periods (14–19). Most of these cases were
published as case reports, except for one study including
10 patients (20). However, four of these patients were
treated for !10 days due to adverse effects, although
these adverse events may have been unrelated to
mifepristone therapy. Moreover, only 12 patients were
treated with mifepristone for CS for more than 2 weeks.
All of these patients showed rapid regression of clinical
signs of cortisol excess suggesting that mifepristone
could become a valuable treatment option in poorly
controlled hypercortisolism. Adverse events included
nausea and fatigue, which could be attributed to
adrenal insufficiency in three cases. These scarce data
also drew attention to the limitations of biochemical
parameters for follow-up as the blockade of glucocorti-
coid receptors by mifepristone may lead to variable
increase in plasma ACTH and consequently cortisol
concentrations (12, 16). Thus, the diagnosis of both
persistent hypercortisolism and adrenal insufficiency is
difficult and largely based on clinical assessment and
close follow-up.
Owing to the lack of sufficient clinical data on
mifepristone in cases of glucocorticoid excess, we
decided to evaluate retrospectively the use of mifepris-
tone as a treatment of CS in seven European centers.
We report here the results of mifepristone therapy in
20 patients. Owing to the various etiologies of CS,
we divided this group into malignant and benign CS.
We tried to define the efficacy and adverse events of
mifepristone to better define the potential role of this
drug in endogenous glucocorticoid excess.Patients and methods
We retrospectively evaluated the effectiveness and
tolerability of mifepristone. We included in our study
20 patients with CS who had been treated with
mifepristone (Mifegyne, Exelgyn Laboratories, Paris,
France; Mifepristone, HRA Pharma, Paris, France).
These patients were followed in seven European
centers: France (Marseille nZ4, Paris nZ1,
Le Kremlin-Bicetre nZ2, Lille nZ1), Germany (Wu¨rzburg,
nZ9), Italy (Orbassano nZ2), and Spain (Alicante,
nZ1). Mifepristone was used on a compassionate basis
after all patients had given their written informed
consent; they had previously received detailed infor-
mation on the potential side effects and benefits of
mifepristone. Patient charts were retrospectivelywww.eje-online.organalyzed in detail for changes in clinical status, adverse
events, and changes in standard biochemical and
hormonal parameters.
The diagnosis of CS was based on the combination of
clinical features of hypercortisolism and biochemical
assessment according to recommended guidelines (21).
The study population comprised 13 females (including
five post-menopausal women) and seven males, with a
mean age of 48.5 years (range 20–63) at the time of
diagnosis of CS (Table 1). None of them presented cyclic
CS. Mifepristone was initiated due to the lack of efficacy
(nZ6) or limited tolerance (e.g. hepatotoxicity) (nZ7)
of previous medical treatments, increase in liver
enzymes due to metastatic disease leading to contra-
indication for adrenostatic drugs (nZ3) or as additional
symptomatic therapy in combination with metyrapone
or etomidate (nZ2). In these two patients, metyrapone
and etomidate were considered as only partially
effective, and the dose was not modified during
mifepristone treatment. In addition, mifepristone was
given to two patients with CD as first adjunctive
treatment after unsuccessful transsphenoidal surgery
(nZ2). All patients had undergone complete clinical
and hormonal evaluation prior to mifepristone treat-
ment. In all centers, efficacy and adverse events of
mifepristone were assessed every 15–30 days by careful
clinical evaluation (clinical signs of hypercortisolism,
psychiatric symptoms, clinical signs, and symptoms
suggestive of adrenal insufficiency, blood pressure)
or earlier if justified by the patient’s condition. Every
15–30 days biochemical follow-up included control of
serum electrolytes, liver enzymes, and kidney function.
In diabetic patients, frequent glycemic controls were
performed with modification of diabetes treatment, if
necessary. TSH levels were measured after 3–6 months
of treatment or in case of clinical evidence of
hypothyroidism, as one case of Hashimoto thyroiditis
has been described previously during mifepristone
therapy (20). Random samples of ACTH and serum
cortisol concentrations were taken in monthly intervals
(during outpatient visits). Owing to its antiprogestin
effects, mifepristone has been reported to induce
endometrial hyperplasia (22). Accordingly, transvaginal
ultrasound examination was performed in a patient of
our series treated for 18 months, as previously
recommended. All adverse events occurring during
treatment were recorded with special attention to the
problems of adrenal insufficiency and hypokalemia.Results
Individual data of the 20 patients treated with
mifepristone for CS are given in Table 1. Mifepristone
was initiated at a median dose of 400 mg/day (range
200–1000). The initial dose was decided by each
investigator and varied with the severity of clinical
signs of hypercortisolism. The median maximal dose
Table 1 Individual data of the 20 patients treated by mifepristone.
Previous treatments Pre-mifepristone
Etiology Sex/age Surgery Anticortisolic drugs Clin. signs Psy. signs Hypertension HypoK Diab.
1 ACC M/63 Y Mitotane C C C C C
2 F/39 Y Mitotane C K C C K
3 F/52 Y Mitotane C K C K K
4 F/52 Y Mitotane C K C K C
5 F/45 Y Mitotane, ketoconazole C K K K K
6 F/63 N Mitotane, ketoconazole C K C K K
7 M/20 Y Mitotane, ketoconazole C K C C C
8 F/47 Y Mitotane, ketoconazole C K C K K
9 F/38 N Mitotane, metyrapone C K K K K
10 F/44 Y Mitotane, metyrapone C K K K K
11 M/64 Y Mitotane, metyrapone C K K K K
12 M/52 N Mitotane, etomidate C C K C C
13 EAS M/55 N Etomidate, metyrapone C K K C C
14 F/43 N Ketoconazole C C C C C
15 F/38 Y Ketoconazole C K C C K
16 CD M/45 Y Ketoconazole C K K K K
17 M/56 Y Ketoconazole C K K K K
18 F/50 N None C C K C K
19 F/45 N None C K K K K
20 BAH F/52 N Ketoconazole C K C C C
Etiology: ACC, adrenocortical carcinoma; CD, Cushing’s disease; BAH, bilateral adrenal hyperplasia; EAS, ectopic ACTH secretion. Sex/age: F, female;
M, male; age in years. Previous treatment: surgery, Y when surgery was performed before mifeptsotone, N when no surgery was performed. Pre-mifepristone,
clinical or biochemical signs before mifepristone treatment; clin. signs, clinical signs of hypercortisolism (hirsutism, bruising, facial fullness, edema, truncal
obesity); psy. signs, psychiatric signs or cognitive deficit; hypertension, high blood pressure level (O140/90 mmHg); hypoK, low serum potassium level
(!3.5 mmol/l); diab., diabetes; for each criterion, C is marked when the criterion was reported, K when the criterion was absent.
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The maximal dose was decided by each investigator
according to clinical efficacy and tolerance (mainly
blood potassium level, signs of adrenal insufficiency).
The median duration of treatment was 2.5 months
(5 days to 24 months). Efficacy and adverse events of the
treatment are reported in Table 2.Mifepristone in malignant CS
Effectiveness and adverse events in patients with
ACC Twelve patients received mifepristone for advanced
ACC. Nine of them were treated unsuccessfully by
surgery, cytotoxic chemotherapy, and/or mitotane,
two were treated by chemotherapy and mitotane only,
and one received only mitotane for a few days, which
was then stopped due to a sharp increase in liver
enzymes (patient no. 12, Table 1). Anticortisolic drugs
including ketoconazole (nZ4), metyrapone (nZ3) or
etomidate (case no. 12), had been used without sufficient
response or were stopped due to poor tolerance. The
median starting dose of mifepristone was 400 mg/day
(200–1000 mg) with a median maximal dose of
600 mg/day (400–2000) and a median duration of
treatment of 2 months (5 days to 6 months).
In eight patients (66%), the clinical signs of
hypercortisolism improved rapidly within the first
month. In these cases, both patient and attending
physician judged the treatment as success. However, in
most cases symptoms did not disappear completely.Psychiatric symptoms improved within the first week in
one of two affected patients and blood pressure
decreased in four of seven patients with hypertension
(57%). Cessation of insulin treatment and switch to
oral drugs was possible in one out of four patients
with diabetes mellitus. In three out of four patients with
low serum potassium prior to mifepristone, hypokale-
mia worsened during mifepristone treatment requiring
high doses of supplemental potassium (up to 16 g/day),
spironolactone (up to 100 mg/day), and, in case no. 12,
cessation of mifepristone within 1 week of treatment.
In patient no. 1, low serum potassium concentrations
remained unchanged during mifepristone. Three other
patients presenting initially with normal serum
potassium concentrations developed moderate to severe
hypokalemia during treatment with mifepristone. Thus,
7 out of 12 patients (58.3%) experienced significant
problems with serum potassium during mifepristone
treatment.
Mifepristone treatment was stopped due to death or
tumor progression (nZ8), lack of significant benefit
(nZ2), and uncontrolled severe hypokalemia (nZ1).
None of the patients died because of adverse effects
of mifepristone. Patient no. 9 is still on treatment after
3 months with clinical signs of hypercortisolism
improved despite tumor progression.
Effectiveness and adverse events in patients with
EAS A total of three patients were treated with
mifepristone for metastatic EAS (thymic carcinoma
nZ1, small cell lung cancer nZ2). All had beenwww.eje-online.org
Table 2 Efficacy and adverse events of mifepristone in the 20 patients of the series.
During mifepristone treatment
Etiology
Dose
initial/final
Duration
(months)
Clin.
signs
Psy.
signs Hypertension HypoK Diab.
Adr.
Ins.
Reason for cessation of
mifepristone treatment
1 ACC 1000/1000 6 Y Y Y 4 Y Death (tumor progression)
2 400/400 2.5 Y K 4 [ K Death (tumor progression)
3 400/600 3 Y K Y [ K Death (tumor progression)
4 400/600 3 Y K Y [ 4 Death (tumor progression)
5 400/2000 1 4 K K [ K No significant benefit
6 600/600 2 4 K 4 K K [ No significant benefit
7 600/1200 1 Y K Y [ 4 [ Death (tumor progression)
8 400/1200 2 4 K 4 [ K Death (tumor progression)
9 400/600 3 Y K K K K Ongoing treatment
10 200/600 2 Y K K K K Tumor progression
11 200/400 1.5 Y K K K K Death (tumor progression)
12 600/600 0.25 4 4 K [ 4 Uncontrolled hypokalemia, cessa-
tion after 1 week of treatment
13 EAS 400/600 1 Y K Y [ Y Tumor progression, hypokalemia
14 600/600 2 Y Y [ [ Y Bilateral adrenalectomy
15 400/800 18 Y K [ [ K Ongoing treatment
16 CD 400/800 12 Y K K K K Bilateral adrenalectomy
17 600/1200 24 Y K K K K [ Radiosurgical treatment efficacy
18 600/600 0.5 4 Y K 4 K Neurosurgical treatment made
possible due to psychosis
improvement
19 600/600 3 Y K [ [ K Ongoing treatment
20 BAH 600/600 6 Y K K 4 Y Bilateral adrenalectomy
Etiology: ACC, adrenocortical carcinoma; CD, Cushing’s disease; BAH, bilateral adrenal hyperplasia; EAS, ectopic ACTH secretion. Dose: mg/day. In the
column « during mifepristone treatment,4 when the criterion was unchanged, [ if the criterion appeared or was worsened during the treatment, K if the
criterion was still absent, Y if the criterion decreased or disappeared with the treatment; Adr. Ins., clinical signs during the treatment were evocative of adrenal
insufficiency (C), or no sign of adrenal insufficiency was present (K); note that patients 2, and 14 presented severe fatigue during the treatment.
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dose was 400 mg/day (400–600 mg) with a median
maximal dose of 600 mg/day (600–800 mg), and
a median duration of treatment of two months
(1–21 months). Patient no. 13 was treated concomi-
tantly with metyrapone, making it difficult to correctly
interpret the results. Clinical signs of hypercortisolism
improved in all patients. One patient with severe psychosis
showed rapid improvement during the first week after
initiation of mifepristone. Two patients who presented
with high blood pressure and low serum potassium
experienced worsening of hypokalemia and hypertension
during mifepristone treatment and required high doses
of spironolactone (up to 400 mg/day) and potassium
supplementation (up to 20 g/day). Severe hypokalemia
was also observed in the remaining patient who had
moderately lowered serum potassium prior to therapy.
In two patients with diabetes mellitus at diagnosis,
insulin doses could be rapidly decreased allowing good
glycemic control with reduced insulin doses or a switch
to oral antidiabetic drugs. Mifepristone was eventually
stopped due to tumor progression and/or profound
hypokalemia (nZ2). The third patient (patient no. 15)
with metastatic thymic carcinoma is still on treatment. In
this patient, withdrawal of mifepristone after cytotoxic
chemotherapy worsened clinical signs and symptoms
of hypercortisolism and, therefore, treatment with
mifepristone was reinitiated. Presently, she has no
clinical signs of hypercortisolism. Moderate hypokalemiawww.eje-online.organd elevated blood pressure levels are well controlled by
spironolactone and potassium administration after 21
months of treatment.Mifepristone in benign CS
Effectiveness and adverse events in patients with CD
Four patients with CD were treated with mifepristone
in our centers. Two of them underwent unsuccessful
transsphenoidal surgery, in one followed by gamma-
knife radio surgery. The third patient (no. 18)
presented with severe psychosis making surgery
impossible. The fourth patient (no. 19) had no
pituitary adenoma image on magnetic resonance
imaging and ketoconazole was poorly tolerated. The
median starting dose of mifepristone was 600 mg/day
(300–600 mg), median maximal dose 700 mg/day
(600–1200), and median duration of treatment was
9 months (0.5–24 months).
Clinical signs of hypercortisolism improved rapidly in
three out of four patients (75%). The patient with
psychosis showed rapid improvement of psychiatric
symptoms within the first week of treatment. None of
the patients had hypertension. However, patient no. 19
developed high blood pressure and severe hypokalemia
during mifepristone. In one patient (no. 18), low serum
potassium remained unaffected by the treatment with
mifepristone. In all patients, ACTH and cortisol levels
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pretreatment levels).
Mifepristone was eventually stopped in three patients
because of bilateral adrenalectomy (nZ1), eventual
efficacy of gamma-knife radio surgery (nZ1), and
neurosurgical treatment after regression of psychosis
(nZ1). Patient no. 19 is still on treatment six months
after initiation of mifepristone therapy.
Effectiveness and adverse events in a patient with
bilateral adrenal hyperplasia This patient was
treated with mifepristone (600 mg/day) because of
severe clinical signs of hypercortisolism, intolerance to
ketoconazole, and refusal of bilateral adrenalectomy.
Signs of hypercortisolism and hypertension improved
progressively during the first three months of treatment.
Hypokalemia was present before initiation of mifepris-
tone and remained unchanged during treatment.
Metformin treatment could be stopped after one
month of treatment, and HbA1c decreased from 7.1 to
6.4% after six months of mifepristone. Eventually, the
patient underwent bilateral adrenalectomy after six
months of treatment with mifepristone.Adrenal insufficiency during mifepristone
treatment
Three of our 20 patients presented clinical signs
suggestive of adrenal insufficiency (fatigue, nausea,
and vomiting). All were treated by dexamethasone
followed by a reduction of mifepristone dose to 50% of
the last dosage prior to adrenal insufficiency. Patients
received 1 mg dexamethasone/400 mg mifepristone as
recommended previously (23). Two patients reported
extreme fatigue, but no other clinical signs of adrenal
deficiency (patients nos 3 and 14). Their treatment was
not modified.Other potential adverse effects of mifepristone
One non-diabetic patient had a transient episode of
hypoglycemia. No increase in liver enzymes or altera-
tions in thyroid function or kidney function was
observed in relation to mifepristone treatment. In the
female patient (patient no. 15) who received mifepris-
tone for 18 months, no endometrial hyperplasia was
observed.Discussion
The antiglucocorticoid activity of mifepristone is well
established in vitro (14). However, in long-term studies
mifepristone has been mainly used as an anti-progestin
in meningioma, myoma or other progesterone-
dependent diseases (24, 25). It is used as an
antiglucocorticoid in patients with hypercortisolismand was hampered by the controversy related to its
use for inducing abortion leading to legal restrictions in
several countries. Accordingly, as shown in Table 3,
only 21 patients (including two children) have been
treated by mifepristone for CS (14, 15, 17, 20, 22,
26–29). Thus, our study of 20 patients doubles the
database of mifepristone treatment for CS and, there-
fore, allows a better appreciation of its effectiveness and
adverse effects.
Our study clearly indicates that mifepristone has
significant potential to improve clinical signs and
symptoms related to CS. Of note, all four patients not
benefitting from mifepristone suffered from very
advanced ACC (the fifth patient, who presented rapid
regression of psychosis signs, was only treated for
15 days). In general, most of our patients were heavily
pretreated and, in most cases, anticortisolic drugs had
failed to control CS or were not tolerated. An important
advantage of mifepristone is the rapid onset of its action
making it especially helpful for patients presenting with
psychosis. In three out of four patients, psychosis signs
indeed disappeared within one week of therapy.
Our study highlights two main challenges in the
treatment of patients with CS with mifepristone:
hypokalemia and adrenal insufficiency. In our study,
55% patients presented relevant hypokalemia. The
percentage of hypokalemia in our study is higher than
the 20% previously reported (16). In CS, hypokalemia is
directly related to glucocorticoid excess as massive
hypercortisolemia leads to incomplete renal inacti-
vation of cortisol by 11-b-dehydrogenase, and hence
mineralocorticoid excess (30). As mifepristone blocks
only glucocorticoid action, the mineralocorticoid
activity of cortisol excess is not affected by mifepristone
treatment, thus leading to hypokalemia. On the
contrary, mifepristone may lead to an increase of
plasma ACTH and consecutively of cortisol levels in
some patients with CS, particularly with CD due to
alterations in negative feedback. Other mechanisms
that probably contributed to the higher incidence of
hypokalemia in our study may be related to the fact that
in many patients adrenostatic therapy was stopped prior
to mifepristone treatment because of drug intolerance.
Thus, in these patients, increase in cortisol concen-
trations could be related to cessation of adrenostatic
therapy or tumor progression, leading to hypercortiso-
lism and severe hypokalemia. Furthermore, even if this
mechanism seems less likely, it has been shown that
progesterone acts as an anti-mineralocorticoid and the
antiprogestin activity of mifepristone may have reduced
this anti-mineralocorticoid action of endogenous pro-
gesterone further enhancing mineralocorticoid excess
(31). In many of our cases, profound hypokalemia was
thus probably multifactorial. However, the fact that
severe hypokalemia was observed even with the use of
spironolactone and potassium supplementation draws
attention on the fact that hypokalemia may become
a treatment limiting side-effect of mifepristone, mainlywww.eje-online.org
Table 3 Efficacy and adverse effects of mifepristone in the 21 patients of the literature.
Sex/age Etiology Dose Duration
Clinical
improvement Adverse effects References
1 F/45 ACC 5–22 mg/kg 2 Yes (20)
2 F/32 ACC 400 2 Yes (29)
3 F/NA ACC 30–20 mg/kg 4 Yes Vaginal bleeding, hypoglycemia,
water retention
(18)
4 M/62 ACC 400 9 Yes (19)
5 M/43 ACC 800–400 0.5 Yes Hypoglycemic episodes, increase in
eosinophils
(29)
6 M/36 EAS 5–22 mg/kg 10 Yes Hashimoto thyroiditis, gynecomastia,
impotence, inhibition of cortisol
synthesis
(20)
7 M/42 EAS 5–22 mg/kg 12 Yes Nausea, gynecomastia (20)
8 F/63 EAS 5–22 mg/kg 4 Yes Adrenal insufficiency (20)
9 F/55 EAS 5–22 mg/kg 2.25 Yes (20)
10 F/46 EAS 800–1600 0.3 Yes (15)
11 M/25 EAS 5–20 mg/kg 2.25 Yes (28)
12 F/2 EAS 25–100 thrice/day 2 Yes (14)
13 F/43 EAS 600 2 Yes Hypokalemia, myelemia (17)
14 F/38 EAS 800 10 Yes (17)
15 F/38 AA 5–22 mg/kg 1.5 Yes Nausea (18)
16 M/51 CD 400–2000 18 Yes Severe hypokaliemia, adrenal crisis (26)
17 F/14 NCS 400 8 Yes Endometrial hyperplasia, transient
rash, Hashimoto’s thyroiditis
(22)
18 NA NA NA !1 NE Hypotension (20)
19 NA NA NA !1 NE Pneumocystis carinii pneumonia (20)
20 NA NA NA !1 NE Severe nausea, prostration (20)
21 NA NA NA !1 NE Nausea, inhibition of cortisol
synthesis
(20)
Etiology: ACC, adrenocortical carcinoma; CD, Cushing’s disease; AA, adrenal adenoma; EAS, ectopic ACTH secretion; NCS, normocortisolemic Cushing’s
syndrome; NA, not available. Dose: mg/day. Duration: months. Clinical improvement: NE, not available. Adapted from ref. (16).
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cases, a combination of mifepristone with anticortisolic
drugs may ameliorate treatment-induced hypokalemia.
Of note that hypokalemia was rapidly reversible (within
48 h) after cessation of mifepristone treatment.
The other important aspect in the management of
patients receiving mifepristone is the risk of adrenal
insufficiency. During mifepristone treatment, adrenal
insufficiency can only be assessed by clinical obser-
vation, as cortisol and ACTH concentrations are either
elevated or not altered by mifepristone treatment.
As outlined above, high cortisol levels may cause
overstimulation of mineralocorticoid receptors leading
to low serum potassium concentrations and even
elevated blood pressure levels further hindering the
assessment of adrenal insufficiency. Key clinical features
are weakness, fatigue, nausea, vomiting, and hypogly-
cemic episodes. In our series, three patients presented
clinical signs suggestive of adrenal insufficiency leading
to therapeutic problems. This result is quite similar to
previous reports. Out of 19 adult patients with CS
described previously, there were five events of adrenal
insufficiency based on clinical assessment (16). Admin-
istration of dexamethasone led to rapid reversal and was
highly effective in treatment of mifepristone-induced
adrenal insufficiency. Dexamethasone is superior to
intravenous hydrocortisone because of its high affinitywww.eje-online.orgto the glucocorticoid receptor and its lack of miner-
alocorticoid activity (23). However, it should be given
for at least two days because of the prolonged half-life of
mifepristone (90 h). Monitoring of patients with CS
receiving mifepristone is demanding and requires
particular attention to detect and treat adrenal
insufficiency. Careful education of the patients is also
mandatory.
The median dosage to control CS in our study was
lower than reported previously. This may be related to
different formulations of the drug, or because of different
levels of cortisol secretion. Based on our study, it
seems that most of the patients can be controlled with
a daily dose of 400–800 mg and that a daily dose
above 1000 mg is probably not more effective but may
be associated with higher toxicity. We therefore,
recommend to start with a daily dosage of 200–400 mg
and to increase the dose according to clinical efficacy
(e.g. blood pressure) and tolerance (blood potassium
level, signs of adrenal insufficiency). In patients in whom
rapid improvement is needed (e.g. psychosis), it seems
reasonable to increase the dosage every three days by
200 mg. In all other patients, dosage adjustments in
every two weeks may be preferable.
The potential risks and benefits of mifepristone have
to be weighed against alternative treatment options.
In comparison with mifepristone, the main advantage of
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cortisol concentration, whereas during mifepristone
cortisol concentration provides no guidance for treat-
ment. However, most of the time, other anticortisolic
drugs also expose patients to frequent and/or severe side
effects without superior efficacy (27). Ketoconazole has
been shown to be highly useful in the treatment of CS
(9). However, serious and life-threatening hepatotoxi-
city has been described (32). Moreover, ketoconazole is
no longer available in some European countries (e.g.
Germany). Metyrapone, an inhibitor of 11-b-hydroxylase,
is not easily available in several European countries
and may also be associated with significant side
effects (10). Etomidate induces profound inhibition of
11-b-hydroxylase also in non-hypnotic doses. However,
it can only be used intravenously and, therefore, is not
well-suited for long-term treatment (33). Similarly, the
use of mitotane is not without difficulties. It has a
narrow therapeutic window and it often takes several
weeks to months to reach plasma target levels.
Numerous side effects of mitotane have been reported,
and a significant percentage of patients may not tolerate
long-term mitotane therapy due to gastrointestinal
and/or neurotoxic adverse events (6–8, 27). Thus,
treatment with mifepristone may be of a significant
value in the medical treatment of CS in a high
percentage of cases.
Our study has several limitations: it is a multicenter
and retrospective report suffering from the classical
drawbacks of this type of investigations. Secondly, in
some patients, mainly with adrenal carcinoma, mife-
pristone was combined with adrenostatic drugs or
chemotherapy. However, this concomitant treatment
was not altered during mifepristone treatment. Third,
due to its mechanism of action, biochemical evaluation
(ACTH and cortisol levels) of the efficacy of mifepristone
is virtually impossible. Thus, the efficacy of mifepristone
must be based on clinical criteria of CS. Although these
criteria are in part subjective, they were successfully
used for evaluation and dose adjustment. Finally, only
a small number of patients were finally enrolled for
each etiology of CS. Our results should thus be
confirmed by prospective studies organized in special-
ized centers for CS.
In conclusion, mifepristone exerts strong antigluco-
corticoid effects in patients with CS, leading to rapid
clinical improvement with acceptable side effects. The
risk of adrenal insufficiency requires close monitoring
by an experienced endocrinologist and careful patient
education. Hypokalemia may occur frequently due to
the mineralocorticoid activity of high serum cortisol
concentrations and may require potassium supple-
mentation and spironolactone for correction. Thus, in
carefully selected patients, particularly when anti-
cortisolic drugs are contraindicated or ineffective,
mifepristone is a valuable and powerful tool to improve
the clinical signs of hypercortisolism.Declaration of interest
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